Macomics, The Macrophage-Based Drug Discovery Company, Secures £4.24M Expansion Financing, And Appoints Ceo, Cso And Vp Immunology
Macomics, The Macrophage-Based Drug Discovery Company, Secures £4.24M Expansion Financing, And Appoints Ceo, Cso And Vp Immunology
07/29/21, 7:34 AM
Location
edinburghMoney raised
£4.24 million
Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has closed a follow-on financing of £4.24 million from its 2020 Seed round, bringing the total amount raised to £7.44m.
Company Info
Location
edinburgh, scotland, united kingdom
Additional Info
– www.macomics.com
Macomics Ltd is an immuno-oncology company with world-leading expertise in macrophage biology, developing precision medicines to modulate macrophages for the treatment of cancer. The company is progressing a diversified portfolio of therapies targeting disease specific tumour associated macrophages (‘TAMs’) towards the clinic. Its target discovery platform enables identification and validation of novel macrophage therapeutic targets and is based on its deep understanding of macrophage biology.
Macomics was co-founded in 2019 by Prof. Jeffrey Pollard and Dr. Luca Cassetta, University of Edinburgh, internationally recognised leaders in macrophage biology. It has R&D and office facilities in Edinburgh and Cambridge, UK and is backed by Epidarex Capital, Scottish Enterprise, and Caribou Property Limited.
Follow us on LinkedIn and https://twitter.com/MacomicsL